Literature DB >> 7453188

Serum zinc, serum copper, and the Cu/Zn ratio in patients with epidermoid cancers of the head and neck.

J A Garofalo, E Erlandson, E W Strong, M Lesser, F Gerold, R Spiro, M Schwartz, R A Good.   

Abstract

Serum zinc levels (SZL), serum copper levels (SCL), and the Cu/Zn ratio were evaluated in 50 patients with epidermoid cancer of the head and neck to treatment with respect to site and stage of disease. There was no significant difference in these parameters compared to healthy normal controls. We could not appreciate any diagnostic or prognostic value in these parameters in patients with head and neck cancer. There was, however, a sex-related difference for SZL in men with oral cavity and women with laryngeal lesions, and a trend toward decreasing SZL and increasing SCL and the Cu/Zn ratio with advanced stage of disease.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7453188     DOI: 10.1002/jso.2930150413

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

Review 1.  Nutrition and immunity.

Authors:  R A Good
Journal:  J Clin Immunol       Date:  1981-01       Impact factor: 8.317

2.  Prophylaxis with oral zinc sulfate against radiation-induced oropharyngeal mucositis in patients with head and neck cancer: Protocol for a meta-analysis of randomized controlled trials.

Authors:  Ting Shuai; Li-Juan Yi; Xu Tian; Wei-Qing Chen; Hui Chen; Xiu-E Li
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

3.  The prognostic value and immune landscape of a cuproptosis-related lncRNA signature in head and neck squamous cell carcinoma.

Authors:  Yao Jun Li; Hai Yan Li; Quan Zhang; Sheng Li Wei
Journal:  Front Genet       Date:  2022-07-22       Impact factor: 4.772

4.  Serum and tissue zinc in epithelial malignancies: a meta-analysis.

Authors:  Jaromir Gumulec; Michal Masarik; Vojtech Adam; Tomas Eckschlager; Ivo Provaznik; Rene Kizek
Journal:  PLoS One       Date:  2014-06-18       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.